For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Blueprint Medicines Corporation

Calculating rank

USPTO Granted Patents = 72

CIPO Patents = 1

EPO Patents = 24

Trademarks = 8

Forward Citations = 977

Loading Chart...

Loading Chart...

60 inventors (with patents filed for the assignee):

Joseph L Kim (40 out of 66 patents)

Douglas Wilson (23 out of 35 patents)

Brian Lewis Hodous (21 out of 45 patents)

4. Kevin J Wilson (20 out of 43 patents)

5. Chandrasekhar V Miduturu (20 out of 22 patents)

6. Natasja Brooijmans (17 out of 17 patents)

7. Jason D Brubaker (16 out of 47 patents)

8. Neil Bifulco (16 out of 20 patents)

9. Lucian V DiPietro (13 out of 25 patents)

10. Steven Mark Wenglowsky (12 out of 12 patents)

11. Yulian Zhang (12 out of 30 patents)

12. Thomas A Dineen (10 out of 10 patents)

13. Nicolas Stransky (9 out of 9 patents)

14. Emanuele Perola (9 out of 44 patents)

15. Paul E Fleming (7 out of 33 patents)

Core Competencies:

EGFR Inhibitors

RET Inhibitors

MAP4K1 Inhibitors

Activin Receptor-Like Kinase

Fibroblast Growth Factor Receptor

NTRK Disorders

CDK2 Inhibitors

KIT Disorders

PDGFRA Disorders

Pyrrolopyridines

Pyrimidine Derivatives

Pyrrolotriazine Derivatives

72 patents: Sort by Forward Citations

1. 12773409 - Treatment of eosinophilic disorders with avapritinib (2026-10-27),

2. 12698290 - Synthetic methods and intermediates for producing compounds for treating KIT- and PDGFRA-mediated diseases (2026-08-04),

3. 12686673 - Pyrimidine compounds, compositions, and medicinal applications thereof (2026-07-21),

4. 12668585 - Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors (2026-06-30),

5. 12662465 - EGFR inhibitors (2026-06-23),

6. 12655143 - Process for preparing an activin receptor-like kinase inhibitor (2026-06-16),

7. 12655129 - Heterocyclic EGFR inhibitors for use in the treatment of cancer (2026-06-16),

8. 12624043 - Compositions useful for treating disorders related to kit (2026-05-12),

9. 12595265 - Inhibitors of activin receptor-like kinase (2026-04-07),

10. 12583856 - Inhibitors of protein kinase A (2026-03-24),

11. 12552795 - PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES (2026-02-17),

12. 12545684 - CDK2 inhibitors (2026-02-10),

13. 12448379 - Wild type kit inhibitors (2025-10-21),

14. 12252494 - Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis (2025-03-18),

15. 12202844 - MAP4K1 inhibitors (2025-01-21),

Company Overview

Blueprint Medicines Corporation, based in Cambridge, MA, specializes in developing targeted therapies for cancer. The company focuses on innovative treatments that address specific genetic drivers of cancer, particularly through its work with EGFR inhibitors, RET inhibitors, and MAP4K1 inhibitors. Additionally, Blueprint Medicines is advancing therapies for conditions related to NTRK disorders and KIT disorders, emphasizing precision medicine to improve patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

72 Patents

#38 in Cambridge, MA

#283 in Massachusetts

#5,110 in US

#10,400 in the World

Cambridge, MA, United States of America

Blueprint Medicines Corporation

Forward Citations = 977

60 inventors:

Joseph L Kim (40 out of 66 patents)

Douglas Wilson (23 out of 35 patents)

Brian Lewis Hodous (21 out of 45 patents)

4. Kevin J Wilson (20 out of 43 patents)

5. Chandrasekhar V Miduturu (20 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Blueprint Medicines Corporation. Retrieved from https://idiyas.com/company/blueprint-medicines

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…